{"url_path":"/sec/pbsv/10-q/2026/item-4","section_key":"item-4","section_title":"Item 4 CONTROLS AND PROCEDURES.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1304161/0001654954-26-005986-index.html","accession_number":"0001654954-26-005986","cik":"0001304161","ticker":"PBSV","issuer_name":"Pharma-Bio Serv, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1304161/0001654954-26-005986-index.html","primary_entity_key":"0001304161","primary_entity_name":"Pharma-Bio Serv, Inc."},"word_count":192,"has_tables":true,"body_markdown":"**ITEM 4. CONTROLS AND PROCEDURES.**\n\n \n\n**Evaluation of Disclosure Controls and Procedures**\n\n \n\nWe carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report on Form 10-Q.\n\n \n\n**Changes in Internal Control Over Financial Reporting**\n\n \n\nBased on an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, there has been no change in our internal control over financial reporting during our last fiscal quarter identified in connection with that evaluation that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.\n\n \n\n \n\n19\n\n*Table of Contents*\n\n  \n\n**PART II– OTHER INFORMATION**"}